4//SEC Filing
Sachs David C. 4
Accession 0001326110-24-000008
CIK 0001326110other
Filed
Jan 2, 7:00 PM ET
Accepted
Jan 3, 9:41 PM ET
Size
9.3 KB
Accession
0001326110-24-000008
Insider Transaction Report
Form 4
Sachs David C.
Chief Financial Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2023-12-31−30,397→ 106,396 total→ Common Stock (30,397 underlying) - Tax Payment
Common Stock
2023-12-31$5.02/sh−10,511$52,765→ 141,928 total - Exercise/Conversion
Common Stock
2023-12-31+30,397→ 152,439 total
Footnotes (3)
- [F1]On December 31, 2023, the Reporting Person's RSUs vested. The closing price of Immunity Bio, Inc.'s common stock on December 29, 2023 was the settlement price used to calculate the shares withheld.
- [F2]Each restricted stock unit ("RSU") represents a contingent right to receive one share of ImmunityBio, Inc. common stock.
- [F3]17,242 of the RSUs vested on December 9, 2021. Five percent (5%) of the remaining 151,989 RSUs (rounded down to the nearest whole share) vested on September 9, 2021; five percent (5%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2022; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) vested on December 31, 2023; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2024; twenty percent (20%) of the RSUs (rounded down to the nearest whole share) will vest on December 31, 2025; and the remaining RSUs will vest on December 31, 2026.
Documents
Issuer
ImmunityBio, Inc.
CIK 0001326110
Entity typeother
Related Parties
1- filerCIK 0001848899
Filing Metadata
- Form type
- 4
- Filed
- Jan 2, 7:00 PM ET
- Accepted
- Jan 3, 9:41 PM ET
- Size
- 9.3 KB